331 related articles for article (PubMed ID: 31576440)
1. Should
Babazadeh NT; Schlund DJ; Cornelius T; Singh JS; Tierney JF; Chen M; Keutgen XM
World J Surg; 2020 Feb; 44(2):604-611. PubMed ID: 31576440
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
4. The utility of
Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
[TBL] [Abstract][Full Text] [Related]
5. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Utility of Total
Tirosh A; Papadakis GZ; Millo C; Hammoud D; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
Gastroenterology; 2018 Mar; 154(4):998-1008.e1. PubMed ID: 29155309
[TBL] [Abstract][Full Text] [Related]
8. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T
Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848
[TBL] [Abstract][Full Text] [Related]
9. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
10. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
11. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis?
Jackson T; Darwish M; Cho E; Nagatomo K; Osman H; Jeyarajah DR
Abdom Radiol (NY); 2021 Jul; 46(7):3179-3183. PubMed ID: 33665733
[TBL] [Abstract][Full Text] [Related]
13. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
14. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
15. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT.
Zahed H; Beauregard JM; Abikhzer G; Rush C; Probst S
Clin Nucl Med; 2023 Jan; 48(1):e12-e15. PubMed ID: 36240803
[TBL] [Abstract][Full Text] [Related]
16. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
[TBL] [Abstract][Full Text] [Related]
17.
Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
[TBL] [Abstract][Full Text] [Related]
18. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
19. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
20. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
